LONDON - Prolifix Ltd., of Abingdon, Oxfordshire, which specializes in the discovery and development of small-molecule drugs that modulate the cell cycle, has entered a collaboration with combinatorial chemistry company Biofocus plc, of Sittingbourne, Kent.

Under terms of the deal, Biofocus will optimize lead molecules for Prolifix's anticancer program. At the same time, Prolifix announced the appointment of Paul Finn to the new post of head of chemistry. Finn, who joins the company from New York-based Pfizer Inc., will manage the partnership with Biofocus. - Nuala Moran